Fusion Antibodies PLC Market Cap ($72.60K)
Market Cap & Net Worth: Fusion Antibodies PLC (FAB)
Fusion Antibodies PLC market cap. Fusion Antibodies PLC (LSE:FAB) has a market capitalization of $72.60K (GBX596.70 Million) as of November 8, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31608 globally and #1154 in its home market, demonstrating a -17.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fusion Antibodies PLC's stock price GBX5.25 by its total outstanding shares 113656253 (113.66 Million). Also see FAB operating cash flow for how efficiently the company converts equity into cash flow.
Fusion Antibodies PLC Market Cap History (2017–2026)
Fusion Antibodies PLC market cap history from 2017 to 2026. Data shows change from $2.95 Million to $72.60K (-29.90% CAGR). Check latest Fusion Antibodies PLC stock price today for real-time trading data and today's change.
Index Memberships
Fusion Antibodies PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$990.01 Million | 0.01% | #377 of 722 |
Weight: Fusion Antibodies PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fusion Antibodies PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fusion Antibodies PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Fusion Antibodies PLC to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.10x
Fusion Antibodies PLC's market cap is 0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $2.95 Million | $1.91 Million | $119.95K | 1.54x | 24.56x |
| 2018 | $753.66K | $2.69 Million | -$699.94K | 0.28x | N/A |
| 2019 | $1.09 Million | $2.18 Million | -$1.26 Million | 0.50x | N/A |
| 2020 | $1.71 Million | $3.90 Million | -$697.00K | 0.44x | N/A |
| 2021 | $1.56 Million | $4.17 Million | -$2.90 Million | 0.37x | N/A |
| 2022 | $622.29K | $4.80 Million | -$1.20 Million | 0.13x | N/A |
| 2023 | $58.77K | $2.90 Million | -$2.60 Million | 0.02x | N/A |
| 2024 | $97.49K | $1.14 Million | -$2.23 Million | 0.09x | N/A |
| 2025 | $193.60K | $1.97 Million | -$1.71 Million | 0.10x | N/A |
Competitor Companies of FAB by Market Capitalization
Companies near Fusion Antibodies PLC in the global market cap rankings as of November 8, 2026. Also see Fusion Antibodies PLC total assets for a full breakdown of the balance sheet.
Key companies related to Fusion Antibodies PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Fusion Antibodies PLC (2017–2026)
Market capitalization of Fusion Antibodies PLC from 2017 to today. Between 2017 and today, Fusion Antibodies PLC's market cap moved from $2.95 Million to $ 72.60K, with a yearly change of -29.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX72.60K | -62.50% |
| 2025 | GBX193.60K | +98.58% |
| 2024 | GBX97.49K | +65.88% |
| 2023 | GBX58.77K | -90.56% |
| 2022 | GBX622.29K | -60.00% |
| 2021 | GBX1.56 Million | -9.27% |
| 2020 | GBX1.71 Million | +57.96% |
| 2019 | GBX1.09 Million | +44.04% |
| 2018 | GBX753.66K | -74.41% |
| 2017 | GBX2.95 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Fusion Antibodies PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $72.60K USD |
| MoneyControl | $72.60K USD |
| MarketWatch | $72.60K USD |
| marketcap.company | $72.60K USD |
| Reuters | $72.60K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fusion Antibodies PLC
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and … Read more